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Table 1. Survival Outcomes of Second Transplants: Patient Characteristics
Patient characteristics All patients (%) Auto/Auto Auto/Allo Allo/Allo
All patients 52 (100%) 12 (23%) 31 (60%) 9 (19%)
Matched Related Donors(MRD) 17 (33%) 0 (0%) 13 (25%) 4 (8%)
Unrelated Donors(URD) 21 (39%) 0 (0%) 18 (35%) 3 (6%)
Autologous Donors 12 (23%) 12 (23%) 0 (0%) 0 (0%)
Syngeneic Donors(Syn) 2 (4%) 0 (0%) 0 (0%) 2 (4%)
Overall survival (1yr) 47% (95% CI 40%-54%) 64% 37% 56%
Overall survival (5yrs) 32% (95% CI 25%-39%) 18% 32% 44%
Relapse at 1 yr 17 (33%) 4 (7%) 12 (23%) 1 (2%) Syn
Treatment related mortality (TRM) at 1 yr 8 (15%) 0 (0%) 5 (10%) 3 (6%)
Cause of death at 1 yr 4 (8%)%MOF;1(2%) GVHD 2 (4%) GVHD;1(2%) PTLD
Acute GVHD(III-IV) 2 (4%) 0 (0%) 1 (2%) 1 (2%)
Chronic GVHD( flare) 18 (35%) 0 (0%) 13 (25%) 5 (10%)
Chronic GVHD(De novo) 2 (4%) 0 (0%) 2 (4%) 0 (0%)
Auto indicates Autologous; Allo, allogeneic; GVHD, graft versus host disease.
Poster Session II S341transplant. Median survival of patients who survived beyond first 30
days after second transplant was 352 days (36-5777 days). The cu-
mulative incidence of grade III-IV acute GVHD was 10 % (n 5 2).
The cumulative incidences of relapse at 1 and 5 years were 33% and
43%respectively. Probabilities of overall survival at 1 and5 yearswere
47% (95% CI 40-54%) and 32% (95% CI 25%-39%), respectively.
Disease recurrence was most frequent primary cause of death in 33%
(n5 18) pts at 1year. TRM was 7% at 30 days; 11% at 100 days and
15% at one year. The causes of TRM at one year included GVHD: 6
% (n5 3), multi organ failure: 7% (n5 4), PTLD 2% (n5 1).
Conclusion: Patients undergoing second transplants can achieve
long term survival beyond 5 years. Relapse, GVHD or early TRM
are still causes of morbidity after second transplant.
370
RADIATION EXPOSURE FROM DIAGNOSTIC PROCEDURES IN ALLOGE-
NEIC STEM CELL TRANSPLANTATION DOES NOT SIGNIFICANTLY IMPACT
OVERALL SURVIVAL OR NON-RELAPSE MORTALITY
Battiwalla, M., Fakhrejahani, F., Klotz, J., Pophali, P., Draper, D.,
Haggerty, J., McIver, Z., Chawla, K., Ito, S., Barrett, J. NHLBI,
NIH, Bethesda, MD
Introduction:Diagnostic radiology procedures in the context of al-
logeneic stem cell transplantation (ASCT) impose an unknown risk
of radiation exposure. We conducted a retrospective study on radia-
tion exposure in the peri-transplant period to define this risk.
Methods: 64 consecutive patients underwent sibling ASCT after
conditioning with TBI 1200 cGy or 400 cGy, fludarabine 125 mg/
m2 and cyclophosphamide 120 mg/kg utilizing CD34+ selected
PBSC and cyclosporine as GVHD prophylaxis. 24 patients received
5x10 e6 CD3+/kg donor lymphocytes selectively depleted of allor-
eactivity by ex vivo photodepletion.
Diagnostic procedures (X-rays, CT Scans, fluoroscopy, and nu-
clear medicine (NM)) were documented for each individual in three
periods (day-30 to 0, day +1-100 and day +101-200). Radiation expo-
sure was calculated using the ‘‘effective dose’’ (ED) in mSv by mea-
surement or from literature review. Overall survival (OS) and
nonrelapse mortality (NRM) were evaluated in 55 subjects who sur-
vived.200 days in univariate analysis andmultivariable Coxmodels.
The variables for the cumulative and the periodic ED were forced
into the models.
Results: Patients underwent a median of 11 X-rays, 10 CT-scans,
0 nuclear medicine studies, and 1 fluoroscopic procedure. The me-
dian cumulative radiation exposure from diagnostic radiology proce-
dures was 91.6 mSv (range 1.2-300.1), equivalent to \10% of
a standard 1200 TBI dose. 29% of the cumulative ED was delivered
fromday -30 to 0, 65% fromday +1-100 and only 6% fromday +101-
200. The relative contributions from CT scans, X-rays, fluoroscopy,
and NM were 88%, 6%, 5% and\1%, respectively.
In univariate analysis, the cumulative dose of incidental radiation
from day -30 to +200 (p\0.03) and from day -30 to +100 (p\0.05)
were significantly associated with OS. The cumulative dose of inci-
dental radiation from day-30 to +100was also significantly associated
with NRM (p\0.03).In multivariable analysis, cumulative doses of radiation lost statis-
tical significance and were displaced by serum creatinine and serum
albumin in the final models for OS and by albumin, acute GVHD
and photodepletion for NRM.
Conclusions: Total radiation exposure from diagnostic radiation
was only a small fraction of radiation utilized in conditioning. CT
scans provided 90% of the radiation exposure. While the cumula-
tive dose of incidental radiation exposure was associated with OS and
NRM in univariate analysis, it was not significant in multivariable
analysis.
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HIGH RESOLUTION 9/10 OR 10/10 HLA MATCHED UNRELATED DONOR
STEM CELLS CONTRIBUTE A BETTER OUTCOME OF TRANSPLANT IN SE-
VERE THALASSEMIA PATIENTS
Hongeng, S., Pakakasama, S., Anurathapan, U., Sirachainan, N.,
Songdej, D., Chuansumrit, A. Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
We reviewed transplant outcome in 34 consecutive children and
adolescents with severe thalassemia who underwent allogeneic stem
cell transplantation with unrelated donors between September
1992 and July 2011.Thefirst cohort 22 patients underwent transplant
from 4/6, 5/6 or 6/6 allele HLA matched unrelated donors and the
second cohort 12 patients underwent transplant from 9/10 or 10/10
HLA matched unrelated donors. The myeloablative conditioning
regimen (MC) consisted of cyclophosphamide, busulfan (BU), flu-
darabine (FLU) and antithymocyte globulin (ATG) and nonmyeloa-
blative (NC) consisted of BU, FLU and ATG. The GVHD
prophylaxis for MC consisted of tacrolimus and MTX and for NC
consisted of tacrolimus andMMF.The purpose of NCwas for toxic-
ity reducing in the patients older than 10 years of age. Of 34 patients,
29 received bone marrow, 4 received peripheral blood and 1 received
cord blood stem cells. The 2-year thalassemia-free survival rate for
the first 22 cohort patients was 71% and 93% for the second cohort
12 patients (p 5 0.045). We suggest that high resolution 9/10 or
10/10 matched unrelated donor stem cells may significantly improve
the thalassemia free survival among severe thalassemia patients
who underwent unrelated donor transplantation.
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CLINICAL OUTCOMES AND COSTS OF SECOND ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION
Khera, N.1, Storer, B.E.1, Chapko, M.K.2, Lee, S.J.1 1Fred Hutchinson
Cancer Research Center, Seattle, WA; 2VA Puget Sound, Seattle, WA
Background: In this era of growing health care costs, the decision to
proceed with a second allogeneic transplant has financial as well as
clinical implications.
Methods: We analyzed all medical costs for the transplant process
from the beginning of conditioning to 100 days after the transplant
for 55 patients who underwent second allogeneic transplants from
1/19/05 to 4/9/10 at the University of Washington/Seattle Cancer
S342 Poster Session IICare Alliance. Clinical information was obtained from the institu-
tional database.Multiple linear regressionwas used to analyze the pa-
tient and transplant characteristics that are associatedwith total costs.
Results:Median age was 50 years (range 21 to 69 years), and 62%
patients were male. Seventy eight percent transplants were for
acute leukemia/MDS. Reasons for second transplant were graft
failure (25%), relapse of original disease (65%) and other causes
e.g. secondary MDS/aplasia (10%). 73% of relapsed patients
were in remission at the time of the second transplant. Non-mye-
loablative conditioning was more common in the second allografts
(75%) than in first allografts (30%) and a higher proportion of sec-
ond allografts were from unrelated donors (76% vs. 43%). In the
first 100 days, relapse occurred in 25% patients and 64% experi-
enced $ grade II acute GVHD. Survival was 78% at 100 days
and 49% at one year after transplant. Regimen related toxicity ac-
counted for 75% of deaths within the first 100 days. The median
total cost in 2010 dollars was $137,600 ($4,500 - $434,200) for
the first 100 days, with approximately $135,600 (0 - $432,200)
for inpatient and $4,100 (0 - $17,200) for outpatient costs. The me-
dian length of hospital stay was 22 days (range 0 to 77 days). Mye-
loablative conditioning, unrelated donors and pulmonary
complications post-transplant were significant predictors of higher
costs for the second transplants.
Table 1. Predictors of costs for second allogeneic transplant
Variable Cost multiplier 95%CI p valuePre-transplant factors
Age<50 1
>50 0.89 0.53-1.47 0.64Disease
Acute leukemia/MDS 1
Lymphoma 0.65 0.28-1.48 0.31
Others 3.18 0.90-11.2 0.08Diseases status
Remission 1
Relapse 0.76 0.38-1.49 0.43Graft source
PBSC 1
BM 0.97 0.26-3.66 0.97
cord blood 0.83 0.35-1.94 0.67Conditioning
myeloablative 1
Non-myeloablative 0.45 0.23-0.86 0.02Year of transplant
Per year 0.88 0.73-1.06 0.18Reason for transplantTable 1. Guidelines for routine serum GM testing followingRelapse 1allogeneic HSCTGraft rejection 1.18 0.64-2.19 0.6
Others 1.48 0.45-4.95 0.52Patients undergoing myeloablative conditioning regimenDonor type
 Day 30-60 post transplant: weekly galactomannanRelated 1
 Day 60+ post transplant: weekly galactomannan for patients on$ 1 mg/kgUnrelated 2.39 1.34-4.25 0.006steroids or ANC < 1000CMV serostatus
Nonmyeloablative conditioning regimennegative 1
 Day 30+: weekly galactomannan for patients on $ 1 mg/kg steroids orpositive 0.83 0.50-1.37 0.48ANC < 1000Post-transplant complications
within 100 days
Death (n 5 12) 0.9 0.37-2.20 0.82
Relapse (n 5 14) 1.15 0.64-2.07 0.65
GVHD (II-IV) (n 5 35) 1.59 0.96-2.64 0.08
VOD (n 5 10)* 1.16 0.52-2.58 0.72
Pulmonary (n 5 5) 2.08 1.05-4.12 0.04
Renal (n 5 9) 1.58 0.59-4.18 0.37
Infection (n 5 29) 1.62 0.96-2.73 0.08*Veno-occlusive disease
Conclusion: Short-term costs of second transplants appear compa-
rable to those of first transplants especially since a majority of them
are non-myeloablative/reduced intensity regimens. Additional work
is neededwith larger numbers of patients to confirm these results and
identify additional characteristics that would predict the group with
the best clinical and economic outcomes.373
CLINICAL UTILITY OF THE GALACTOMANNAN ASSAY AS A SCREENING
TOOL FOR INVASIVE ASPERGILLOSIS FOLLOWING ALLOGENEIC HEMA-
TOPOIETIC STEM CELL TRANSPLANT
Keating, T.M., Casper, C., Fredricks, D. Fred Hutchinson Cancer Re-
search Center, Seattle, WA
Background: Invasive aspergillosis (IA) can result in significant
morbidity for immunosuppressed patients, particularly after alloge-
neic hematopoietic stem cell transplant (HSCT). The serum galac-
tomannan (GM) assay has been utilized as a tool to facilitate early
detection of IA, however its clinical usefulness for screening has
not been well studied. Routine screening was performed at our cen-
ter for patients considered to be at highest risk of IA (Table 1) and
a review was conducted to determine whether this improved case
finding.
Methods: Clinical data, including demographics, transplant history
and GM testing was reviewed for all adult allogeneic transplant re-
cipients seen at our Center in 2008. Probable and proven cases of
IA were identified by chart review of patients with positive culture,
pathology, PCR or GM from serum, bronchoalveolar lavage, or
other clinical site and classified according to EORTC criteria for di-
agnosis of IA. AGMcut-off of$ 0.5 in a single sample defined a pos-
itive result.
Results: A total of 1,939 serum GM assays were performed in 2008
in 239 patients for a mean of 8.1 tests per patient. Six percent (n 5
117) of tests were positive in 49 patients. Of those, 20 patients
(41%) met the diagnosis of IA. The sensitivity of the GM assay in
this screening settingwas 31%with a specificity of 95%and a positive
predictive value of 25%.
There were 32 cases of IA identified in 2008. Thirteen (41%) of
the identified cases clearly met criteria for GM screening at our cen-
ter and only seven of these cases had a positive serum GM prior to
diagnosis. A positive serum GM led to diagnosis of IA in three pa-
tients. Other cases were identified during evaluation of respiratory
tract infection symptoms (n5 13), fever (n5 9), routine radiological
imaging (n5 5), or follow up of previously identified pulmonary dis-
ease (n 5 2).
Conclusions: The GM assay demonstrated poor sensitivity as
a screening tool in a population of adult patients following allogeneic
HSCT. Despite recommendations for routine screening in patients
at highest risk for IA, the galactomannan contributed to case finding
in only three of 32 identified cases. Most cases did not meet recom-
mendations for routine screening and did not have a positive GM
prior to diagnosis. GM has low value as a screening tool in HSCT
when employed using the guidelines described here.374
THE HEMATOPOIETIC CELL TRANSPLANTATION-SPECIFIC COMORBID-
ITY INDEX (HCT-CI) AND SURVIVAL FOLLOWING EXTRACORPOREAL
PHOTOPHERESIS, PENTOSTATIN, AND REDUCED DOSE TOTAL BODY IR-
RADIATION CONDITIONING
Hashmi, S., Oliva, J.L., Liesveld, J.L., Phillips, G.L., Nichols, D.,
Milner, L., Becker, M. University of Rochester, Rochester, NY
Background: The HCT-CI has been reported to be an informative
tool to predict survival after myeloablative and fludarabine-based re-
duced intensity conditioning SCT. Recipient age, disease type, dis-
ease status, and donor relatedness have also been associated with
survival. The specific aims of this study were to describe SCT recip-
ients who received photopheresis, pentostatin, and 2-6Gy total body
